IPN Share Price

Open 83.27 Change Price %
High 84.09 1 Day 0.31 0.38
Low 81.69 1 Week 5.75 7.45
Close 82.97 1 Month 10.43 14.38
Volume 169557 1 Year 30.88 59.28
52 Week High 84.09
52 Week Low 46.01
IPN Important Levels
Resistance 2 85.19
Resistance 1 84.28
Pivot 82.92
Support 1 81.66
Support 2 80.75
EPA France Most Active Stocks
VK 5.32 -6.99%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
VIV 16.32 -3.94%
More..
EPA France Top Gainers Stocks
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
ALSPO 1.32 -15.38%
ASP 4.91 -9.41%
ASP 4.91 -9.41%
ASP 4.91 -9.41%
ASP 4.91 -9.41%
ASP 4.91 -9.41%
XIL 10.72 -8.38%
ALENT 0.75 -7.41%
BUI 11.11 -7.26%
BUI 11.11 -7.26%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 5
As on 24th Feb 2017 IPN Share Price closed @ 82.97 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 61.20 & Strong Buy for SHORT-TERM with Stoploss of 72.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for February
1st Target up-side 75.27
2nd Target up-side 77.78
3rd Target up-side 80.29
1st Target down-side 68.11
2nd Target down-side 65.6
3rd Target down-side 63.09
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.